Jazz Pharmaceuticals
This article contains content that is written like an advertisement. (July 2018) |
Company type | Public |
---|---|
Nasdaq: JAZZ | |
Industry | Biotechnology Pharmaceutical |
Predecessor | Jazz Pharmaceuticals, Inc. Azur Pharma plc |
Founded | March 2005Dublin, Ireland | in
Headquarters | Dublin, Ireland |
Area served | Worldwide |
Key people | Bruce C. Cozadd, Chairman & CEO |
Products | Pharmaceutical drugs |
Brands | |
Revenue | US$1.618 billion (2017)[1] |
US$528.8 million (2017)[1] | |
US$487.8 million (2017)[1] | |
Total assets | US$5.123 billion (2017)[1] |
Total equity | US$2.713 billion (2017)[1] |
Number of employees | ~1,210 (February 2018)[1] |
Website | www |
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1]
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]
Company history & Acquisitions
2010
On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia[5] In the following December, a new patent was issued for Sodium Oxybate [6]
2011
On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge[7]
2012
On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments[8] In September the company successfully sold its Women's Health business to Meda for $95 million [9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia [10]
2014
In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion[11][12]
2016
In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14]
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Jazz Pharmaceuticals |
| |||||||||||||||||||||||||||||||||||||||||||||
References
- ^ a b c d e f g "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018.
- ^ "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
- ^ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
- ^ http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
- ^ "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News. Vol. 34, no. 2. January 15, 2014. p. 10.
{{cite news}}
:|format=
requires|url=
(help) - ^ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
- ^ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN".